样式: 排序: IF: - GO 导出 标记为已读
-
Medicolegal and insurance issues regarding BRCA1 and BRCA2 gene tests in high income countries Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-19 Riccardo Oliva, Simone Grassi, Claudia Marchetti, Francesca Cazzato, Roberta Marinelli, Giovanni Scambia, Anna Fagotti
Hereditary breast and ovarian cancer syndrome is an autosomal dominant cancer susceptibility syndrome mainly due to variants in BRCA1 or BRCA2 genes. Patients presenting with BRCA1 or BRCA2 gene mutations have a lifetime risk of developing breast or ovarian cancer (80% and 40%, respectively). Genetic testing to explore the predisposition to develop cancer represents a pivotal factor in such cases,
-
Small bite fascial closure technique reduces incisional hernia rates in gynecologic oncology patients Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-19 Alli M Straubhar, Cynthia Stroup, Amanda Manorot, Kevin McCool, Aimee Rolston, R Kevin Reynolds, Karen McLean, Olivia de Bear, Jean Siedel, Shitanshu Uppal
Background The potential for the technique of small bite fascial closure in mitigating incisional hernias in gynecologic oncology patients still needs to be investigated. Objective To evaluate the impact of closure of small fascial bites compared with prior standard closure on incisional hernia rates in gynecologic oncology patients. Methods This is a retrospective cohort study comparing patient outcomes
-
Step by step abdominal wall closure in elective midline laparotomy Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-19 M Reyes Oliver- Perez, Oscar Caso-Maestro, Beatrice Conti-Nuño, Rocio Bermejo, Blanca Gil-Ibañez, Alvaro Tejerizo-Garcia
An incisional hernia is a frequent complication after primary elective midline laparotomy, with an incidence of 5–20%, which increases to 40% in specific risk groups.[1 2][1] It is associated with high morbidity, decreased quality of life, and high costs.[1 2][1] Additionally, repair of incisional
-
Obesity paradox: is a high body mass index positively influencing survival outcomes in gynecological cancers? A systematic review and meta-analysis Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-19 Matteo Pavone, Marta Goglia, Cristina Taliento, Lise Lecointre, Nicolò Bizzarri, Francesco Fanfani, Anna Fagotti, Giovanni Scambia, Jacques Marescaux, Denis Querleu, Barbara Seeliger, Chérif Akladios
Objective Obesity represents an exponentially growing preventable disease leading to different health complications, particularly when associated with cancer. In recent years, however, an ‘obesity paradox’ has been hypothesized where obese individuals affected by cancer counterintuitively show better survival rates. The aim of this systematic review and meta-analysis is to assess whether the prognosis
-
Synchronous juvenile granulosa cell tumor and fibroma Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-19 Yi Hua Lin, Ching-Hu Wu, Wei-An Lai
A 67-year-old post-menopausal woman presented with increased abdominal girth, abdominal pain, urinary frequency, and vaginal bleeding. Abdominal CT showed a 17 cm right ovarian multiloculated cystic mass, a 6.5 cm left ovarian mass, and uterine myomas. The patient underwent total hysterectomy and
-
Immature teratoma of the ovary Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-19 Prerna Chadha, Anila Sharma, Meenakshi Kamboj, Anurag Mehta
A patient in her 30s presented with abdominal distension. A CT scan of the abdomen revealed a right ovarian mass. Gross pathological examination showed a 23.5×22×10.5 cm solid and cystic mass. Histopathological examination showed a neoplasm derived from all three germ layers, including large areas
-
Uterine inflammatory myofibroblastic tumor with myxoid predominance: diagnostic challenge Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-19 Miguel Rodrigues, Catarina Ivanova, Ana Felix
Inflammatory myofibroblastic tumors are uncommon neoplasms characterized by myofibroblastic spindle cell proliferation accompanied by inflammatory cells, and commonly exhibiting three main architectural patterns, including a myxoid pattern.[1][1] While uterine inflammatory myofibroblastic tumors are
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 – A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-16 Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, Bradley J Monk, Thomas Herzog, David Cibula, Nicoletta Colombo, Bhavana Pothuri, Jalid Sehouli, Jacob Korach, Joyce Barlin, Christos A Papadimitriou, Toon van Gorp, Debra Richardson, Michael McCarthy, Yoland Antill, Mansoor Raza Mirza, Kai Li, Pratheek Kalyanapu, Brian Slomovitz, Robert L Coleman
Background Patients with advanced/recurrent endometrial cancer have a poor prognosis and limited treatment options. Biomarkers such as tumor protein 53 ( TP53 ) in endometrial cancer can integrate novel strategies for improved and individualized treatment that could impact patient outcomes. In an exploratory analysis of the phase III ENGOT-EN5/GOG-3055/SIENDO study of selinexor maintenance monotherapy
-
Tumoral clearance of the right portal hilar area: surprises beyond ‘no visual disease’ Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-16 Ghanim Khatib, Emine Gulen Kucukbingoz, İrem Hatipoglu, Mehmet Ali Vardar
A woman in her mid 40s was admitted with abdominal pain and weight loss for the last 6 months. The CT scan revealed a 13 cm mass with prominent solid components in the left ovary, retroperitoneal lymphadenopathy, and peritoneal carcinomatosis. No distant organ metastases were reported. The value
-
Role of fertility-sparing surgery and further prognostic factors in borderline tumors of the ovary Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-16 Timo Westermann, Edin Karabeg, Florian Heitz, Alexander Traut, Helmut Plett, Malak Moubarak, Julia Welz, Sebastian Heikaus, Sigurd Lax, Andreas du Bois, Philipp Harter
Objective Borderline tumors of the ovary are a rare group of ovarian neoplasms with distinctive histological features. Considering their favorable prognosis and occurrence at a younger age, fertility-sparing surgery may be considered. Several risk factors have been identified as contributing to a higher recurrence rate, while the impact of pathohistological features varies in the literature. This study
-
Low serum creatinine levels are associated with major post-operative complications in patients undergoing surgery with gynecologic oncologists Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-16 Connor C Wang, Sonya Bharadwa, Olivia W Foley, Issac Domenech, Brenda Vega, Mary Towner, Emma L Barber
Objective Serum creatinine is a byproduct of muscle metabolism, and low creatinine is postulated to be associated with diminished muscle mass. This study examined the association between low pre-operative serum creatinine and post-operative outcomes. Methods This retrospective cohort study utilized the 2014–2021 National Surgical Quality Improvement Program to identify patients undergoing surgery with
-
Association of reviewer experience with discriminating human-written versus ChatGPT-written abstracts Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-16 Gabriel Levin, Rene Pareja, David Viveros-Carreño, Emmanuel Sanchez Diaz, Elise Mann Yates, Behrouz Zand, Pedro T Ramirez
Objective To determine if reviewer experience impacts the ability to discriminate between human-written and ChatGPT-written abstracts. Methods Thirty reviewers (10 seniors, 10 juniors, and 10 residents) were asked to differentiate between 10 ChatGPT-written and 10 human-written (fabricated) abstracts. For the study, 10 gynecologic oncology abstracts were fabricated by the authors. For each human-written
-
Molecular and pathologic data to guide selection of patients with endometrioid endometrial cancer for ovarian preservation Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-11 Beryl L Manning-Geist, Eric Rios-Doria, Ying L Liu, Lora H Ellenson, Qin C Zhou, Alexia Iasonos, Mario M Leitao, Nadeem R Abu-Rustum, Britta Weigelt, Jennifer J Mueller
Objectives To investigate the association of molecular and pathologic factors with concurrent or recurrent ovarian disease to guide ovarian preservation in endometrioid endometrial cancer. Methods Patients with endometrial cancer ≤50 years of age at diagnosis were grouped by elective oophorectomy versus ovarian preservation at staging (January 2010 to June 2021). Tumors were stratified by molecular
-
MIRRORS: a prospective cohort study assessing the feasibility of robotic interval debulking surgery for advanced-stage ovarian cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-11 Christina Uwins, Hasanthi Assalaarachchi, Kate Bennett, James Read, Anil Tailor, James Crawshaw, Jayanta Chatterjee, Patricia Ellis, Simon S Skene, Agnieszka Michael, Simon Butler-Manuel
Objective To establish the feasibility and safety of robotic interval debulking surgery following the MIRRORS protocol (robot-assisted laparoscopic assessment prior to robotic or open surgery) in women with advanced-stage ovarian cancer. MIRRORS is the first of three planned trials: MIRRORS, MIRRORS-RCT (pilot), and MIRRORS-RCT. Methods The participants were patients with stage IIIc-IVb epithelial
-
Correspondence on ‘Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer’ by Luzarraga Aznar et al Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-10 Junwu Zhang, Yun Sun
We read about Luzarraga Aznar et al’s study[1][1] with great interest. In this study, the authors investigated the pattern of first recurrence of disease in patients with endometrial cancer according to molecular classification, and assessed the independent role of molecular profiling in each type
-
Radical vaginal trachelectomy: long-term oncologic and fertility outcomes in patients with early cervical cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-10 Christhardt Kohler, Andrea Plaikner, Kathrin Siegler, Hermann Hertel, Kati Hasenbein, Anja Petzel, Melanie Schubert, Jens-Uwe Blohmer, Gerd Böhmer, Claudia Stolte, Simone Marnitz, Nina Mallmann-Gottschalk, Peter Oppelt, Giovanni Favero, Silke Westphalen, Ingke Hagemann, Peter Martus, Achim Schneider
Objective Radical vaginal trachelectomy is a fertility-preserving treatment for patients with early cervical cancer. Despite encouraging oncologic and fertility outcomes, large studies on radical vaginal trachelectomy are lacking. Method Demographic, histological, fertility, and follow-up data of consecutive patients who underwent radical vaginal trachelectomy between March 1995 and August 2021 were
-
Response to: Correspondence on 'Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer' by Zhang and Sun Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-10 Vicente Bebia, Ana Luzarraga Aznar, Silvia Cabrera
We read with interest Zhang et al's letter[1][1] raising some concerns about the statistical analysis of our work.[2][2] The main issue raised was the low rate of events per variable in some of the multivariate analysis presented. As we are fully aware, low events per variable may lead to
-
First workshop on cervix cancer surgery in Latin America: a hands-on experience from Lima, Perú Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-09 Joan Flaubert Perez Villena, Marco Sánchez Salcedo, Absalon Montoya Guivin, Vladimir Villoslada Terrones, Aldo Lopez Blanco
Cervical cancer represents a major public health issue for Latin American countries, with an estimate of 63 056 new cases and 33 443 deaths annually, according to recent GLOBOCAN reports. Unfortunately, most patients are diagnosed with locally advanced stages. In Perú, the Instituto Nacional de
-
Advancing endometrial cancer management in the era of molecular classification: insights into pattern of recurrence Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-08 Luigi Antonio De Vitis, Francesco Multinu
Following the landmark study of the Cancer Genome Atlas, the classification of endometrial cancer into four groups has reshaped its management: (1) POLE mutated, (2) mismatch repair deficient, (3) p53 abnormal, and (4) no specific molecular profile. Since then, molecular classes have been
-
Progesterone-releasing intrauterine device in the fight against the endometrial cancer pandemic—not the only solution Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-03 Janneke T Wolswinkel, Louis J M van der Putten, Johanna M A Pijnenborg
Endometrial cancer is the malignancy most strongly associated with obesity. To minimize the impact of its rising incidence there is an urgent need for prevention. Combining medical interventions with lifestyle changes will be crucial to reduce the endometrial cancer incidence. Estrogen causes a
-
Comparative study using indocyanine green and patent blue dye for sentinel lymph node biopsy in patients with early-stage cervical cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-03 Benedikt Wess, Christhardt Kohler, Andrea Plaikner, Samer El-Safadi, Thilo Schwandner, Ivo Meinhold-Heerlein, Giovanni Favero
Background Lymphatic involvement is the most important prognostic factor in early-stage cervical cancer. Sentinel lymph node biopsy is a viable alternative to systematic lymphadenectomy and may identify metastases more precisely. Objective To compare two tracers (indocyanine green and patent blue) to detect sentinel nodes. Methods A single-center, retrospective study of women treated due to early-stage
-
Management challenges in low-grade serous ovarian cancer with a BRCA mutation Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Luisa Sanchez-Lorenzo, Lidia Sancho, Teresa Iscar, Rachel Grisham, Luis Chiva
A 45-year-old patient sought gynecological consultation in January 2018 due to persistent severe pelvic pain since August 2017. She had no relevant medical or surgical history. Her family history was significant for two paternal aunts and two cousins diagnosed with breast and ovarian cancer. In the
-
Correction: MILACC study: could undetected lymph node micrometastases have impacted recurrence rate in the LACC trial? Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 BMJ Publishing Group Ltd
Nitecki R, Ramirez PT, Dundr P, et al . MILACC study: could undetected lymph node micrometastases have impacted recurrence rate in the LACC trial? Int J Gynecol Cancer 2023;33:1684-1689. This article has been corrected since it was first published. Author David Cibula’s affiliation has been
-
Intraepithelial tumor-infiltrating lymphocytes shape loco-regional PET/CT spread of locally advanced cervical cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Mathilde Del, Claire Illac, Mathilde Morisseau, Martina Aida Angeles, Anne Ducassou, Sarah Betrian, Guillaume Bataillon, Gwenael Ferron, Elodie Chantalat, Erwan Gabiache, Alejandra Martinez
Background Data suggest an association between positron emission tomography/CT (PET/CT) metabolic metrics and tumor microenvironment in several malignancies, and a potential role of PET/CT to monitor response to immunotherapy. Objective To evaluate the correlation between tumor loco-regional extension and tumor-infiltrating lymphocyte infiltration in locally advanced cervical cancer prior to concurrent
-
Correspondence on “Sentinel lymph node assessment in patients with atypical endometrial hyperplasia: a systematic review and meta-analysis” by Vieira-Serna et al Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 X Mona Guo, Lauren M Lim, Koji Matsuo
We greatly appreciate the summary by Dr Vieira-Serna and colleagues on sentinel lymph nodes (SLN) and endometrial intra-epithelial neoplasia.[1][1] Their conclusion was that SLN assessment is safe and feasible in endometrial intra-epithelial neoplasia and “routine SLN evaluation may not be
-
Response to: Correspondence on “Sentinel lymph node assessment in patients with atypical endometrial hyperplasia: a systematic review and meta-analysis” by Vieira-Serna et al and Restaino et al Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Santiago Vieira-Serna, David Viveros-Carreño, Rene Pareja
We appreciate the comments by Guo et al and Restaino et al on our paper.[1][1] We concur that the gynecologic oncology community has not yet established a universally accepted threshold to determine whether the sentinel lymph node metastasis rate warrants lymph node evaluation in patients with low-
-
Correspondence on ‘Sentinel lymph node assessment in patients with atypical endometrial hyperplasia: a systematic review and meta-analysis’ by Vieira-Serna et al Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Stefano Restaino, Martina Arcieri, Giuseppe Vizzielli
We thank the authors for this well written meta-analysis.[1][1] The topic is of great interest, and there are currently no guidelines regarding the assessment of sentinel lymph node (SNL) in this setting. The authors focused on the rate of positive lymph nodes in cases of hyperplasia or carcinoma in
-
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Tine Ottenbourgs, Toon van Gorp, Frédéric Kridelka, Thaïs Baert, Hannelore Denys, Frédéric Selle, Inge Baas, Anne-Sophie Van Rompuy, Diether Lambrechts, Els Van Nieuwenhuysen
Background Low-grade serous and endometrioid ovarian cancers and adult-type granulosa cell tumors are rare ovarian malignancies that show high estrogen receptor positivity. Recurrences of these subtypes of ovarian cancer are often treated with conventional chemotherapy, although response rates are disappointing. Primary Objective To determine the overall response rate of the combination therapy of
-
Mismatch repair status and surgical approach in apparent early-stage endometrial cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Rhett Morton, Penelope M Webb, Renhua Na, Andreas Obermair, Rhonda Farrell
Objective To test the hypothesis that mismatch repair (MMR) status (as an accurate surrogate marker for microsatellite stability) modifies the effect of surgical approach on oncological outcome for apparent early-stage endometrial cancer. Methods Observational data from a large prospective population study on endometrial cancer were analyzed using target trial methodology and doubly robust methods
-
European Society of Gynaecological Oncology expanded quality indicators and accreditation for cervical cancer management Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Christina Fotopoulou, Ane Gerda Eriksson, François Planchamp, Philippe Morice, Alexandra Taylor, Alina Sturdza, Ovidiu Florin Coza, Michael J Halaska, Fabio Martinelli, Robert Armbrust, Cyrus Chargari
Although the incidence of cervical cancer in Europe is declining it remains a major public health problem, particularly in limited-resourced countries, with wide variations in regional and national management. Cervical cancer is still the leading cause of cancer-related death in women in eastern,
-
Benign Brenner tumor pathology: the ‘dragon fruit sign’ Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Paytra A Klein, Amelia Stapleton Van Doren, Johanna Bringley
Eponymophilia is the practice of naming a medical condition or pathological finding after a person, place, or thing, such as Alzheimer’s disease, Coxsackie virus, or pearls-on-a-string sign.[1][1] The field of obstetrics and gynecology, in particular, has a rich history of eponym usage.[2][2]
-
Mirvetuximab soravtansine: an oasis in the desert? Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Luisa Bonilla, Lawrence Kasherman, Luis Manso, Ainhoa Madariaga
Three common facts arise in discussions about ovarian cancer nowadays. First, systemic therapy was introduced approximately five decades ago and remained largely unchanged for four of those decades. Second, only a fraction of patients possess a reliable predictive marker of response to therapy,
-
Recurrence rates and patterns of recurrence in stage IA p53abn endometrial cancer with and without myometrial invasion Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Amy Jamieson, Marcel Grube, Samuel Leung, Derek Chiu, Amy Lum, Janice S Kwon, Aline Talhouk, Blake Gilks, Stefan Kommoss, Jessica N McAlpine
Objectives Optimal management of patients with stage IA p53abn endometrial cancer without myoinvasion, classified as intermediate risk in the 2020 European Society of Gynaecological Oncology, European Society for Radiotherapy and Oncology, and European Society of Pathology (ESGO-ESTRO-ESP) guidelines, and the 2022 European Society of Medical Oncology (ESMO) guidelines, is currently unclear. Practice
-
Consensus on surgical technique for sentinel lymph node dissection in cervical cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Nicolò Bizzarri, Andreas Obermair, Heng-Cheng Hsu, Enrique Chacon, Anna Collins, Irina Tsibulak, Alex Mutombo, Nadeem R Abu-Rustum, Vincent Balaya, Alessandro Buda, David Cibula, Allan Covens, Francesco Fanfani, Gwenaël Ferron, Michael Frumovitz, Benedetta Guani, Roman Kocian, Christhardt Kohler, Eric Leblanc, Fabrice Lecuru, Mario M Leitao, Patrice Mathevet, Michael D Mueller, Andrea Papadia, Rene
Objective The purpose of this study was to establish a consensus on the surgical technique for sentinel lymph node (SLN) dissection in cervical cancer. Methods A 26 question survey was emailed to international expert gynecological oncology surgeons. A two-step modified Delphi method was used to establish consensus. After a first round of online survey, the questions were amended and a second round
-
The International Gynecologic Cancer Society Preinvasive Certificate Program: building a skilled workforce for the detection and treatment of cervical pre-cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Karen Haney, Ida Ismail-Pratt, Joseph Soon-Yau Ng, Kathleen M Schmeler, Mila Pontremoli Salcedo
Cervical cancer is preventable, yet annual global incidence and mortality rates remain unacceptably high. In 2020, the World Health Organization (WHO) adopted the Global Strategy for cervical cancer elimination with a central goal of screening and treating women with cervical pre-cancer and cancer.
-
Role of endometrial sampling to differentiate between advanced endometrial versus ovarian malignancy: retrospective cohort study Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Nguyen Thao Thi Nguyen, Nicole Diaz, Hadley Reid, Rebecca Previs, Laura J Havrilesky, Angeles Alvarez Secord, Andrew Berchuck
Objective Distinguishing between advanced stage endometrial and ovarian cancer at diagnosis can be challenging, especially when patients do not present with abnormal uterine bleeding. Given emerging systemic therapies specific for ovarian versus endometrial cancers, it has become increasingly critical to establish the correct diagnosis at presentation to ensure appropriate treatment. This study evaluates
-
A computer synoptic operative report versus a report dictated by a surgeon in advanced ovarian cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Alice Bedel, Guillaume Blache, Camille Jauffret, Gilles Houvenaeghel, Max Buttarelli, Laura Sabiani, Navid Mokarram Dorri, Houssein El Hajj, Eric Lambaudie
Objective To evaluate the role of a computer synoptic operative report in enhancing the quality and completeness of surgical reporting for advanced ovarian cancer surgeries. Methods The study was conducted at a tertiary cancer center between January 2016 and September 2021, and the computer synoptic operative report was implemented in May 2019. The study compared two cohorts: the first consisted of
-
Intrauterine manipulator use during laparoscopic hysterectomy for endometrial cancer: association for pathological factors and oncologic outcomes Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Hiroshi Yoshida, Koji Matsuo, Hiroko Machida, Shinya Matsuzaki, Michihide Maeda, Yoshito Terai, Takuma Fujii, Masaki Mandai, Kei Kawana, Hiroaki Kobayashi, Mikio Mikami, Satoru Nagase
Objective To examine the association between intrauterine manipulator use and pathological factors and oncologic outcomes in patients with endometrial cancer who had laparoscopic hysterectomy in Japan. Methods This was a nationwide retrospective cohort study of the tumor registry of the Japan Society of Obstetrics and Gynecology. Study population was 3846 patients who had laparoscopic hysterectomy
-
Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Tiffany Y Sia, Vivian Wan, Michael Finlan, Qin C Zhou, Alexia Iasonos, Oliver Zivanovic, Yukio Sonoda, Dennis S Chi, Kara Long Roche, Elizabeth Jewell, William P Tew, Roisin E O'Cearbhaill, Seth Cohen, Vicky Makker, Ying L Liu, Claire F Friedman, Chrisann Kyi, Dmitriy Zamarin, Ginger Gardner
Objective To evaluate the feasibility and outcomes of performing procedural interventions, defined as surgical resection, tumor ablation, or targeted radiation therapy, for oligoprogressive disease among patients with gynecologic malignancies who are treated with immune checkpoint blockade. Methods Patients with gynecologic cancers treated with immune checkpoint blockade between January 2013 and October
-
Therapeutic role of para-aortic lymphadenectomy in patients with intermediate- and high-risk endometrial cancer: a systematic review and meta-analysis Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Matteo Pavone, Floriane Jochum, Lise Lecointre, Francesco Fanfani, Giovanni Scambia, Denis Querleu, Chérif Akladios
Objective Lymph nodal involvement is a prognostic factor in endometrial cancer. The added value of para-aortic lymphadenectomy compared with pelvic nodal evaluation alone remains a matter of debate in the management of patients with intermediate- and high-risk endometrial cancer. A systematic review and meta-analysis was conducted to assess the prognostic value of para-aortic lymphadenectomy in terms
-
Neuroendocrine neoplasms of the ovary: a review of 63 cases Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Alejandra Flores Legarreta, Reem Saab, Naomi R Gonzales, Gary B Chisholm, Shannon N Westin, R Tyler Hillman, Michael Frumovitz
Objective To describe the clinicopathological characteristics and survival outcomes of ovarian neuroendocrine neoplasms from a curated registry. Methods This is a retrospective cross-sectional study of patients in our registry with confirmed ovarian neuroendocrine neoplasms. We excluded patients with small cell carcinoma not otherwise specified, small cell hypercalcemic type, and those with neuroendocrine
-
Use of indocyanine green for ureteric illumination and visualization Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Helena M Obermair, Santiago Scasso, Joel Laufer, Andreas Obermair
The ureters arise from the renal pelvis and track towards the bladder in close proximity to important vascular structures (aorta and inferior vena cava; common, external and internal iliac vessels), and pelvic organs, which make it vulnerable to intra-operative injury. The risk of ureteric injury at
-
Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Barnabe Bouvarel, Oliver Colomban, Jean-Sebastien Frenel, Cécile Loaec, Charlotte Bourgin, Dominique Berton, Gilles Freyer, Benoit You, Jean-Marc Classe
Objectives The modeled CA-125 elimination constant K (KELIM) is a pragmatic early marker of tumor chemosensitivity in ovarian cancer patients treated with neoadjuvant chemotherapy before interval surgery. The primary objective of this study was to assess the prognostic value of KELIM regarding the feasibility of complete surgery, and secondary objectives were to assess the prognostic value of KELIM
-
Medical cannabis and its effect on oncological outcomes in patients with ovarian cancer treated with PARP inhibitors Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Shira Peleg Hasson, Eliya Shachar, Miriam R Brezis, Akram Saad, Bar Toledano, Nadav Michaan, Ido Laskov, Dan Grisaru, Jeffrey Goldstein, Amir Nutman, Tamar Safra
Background Poly (ADP-ribose) polymerase inhibitors (PARPi) play a pivotal role in ovarian cancer management. With medical cannabis emerging as a novel component of supportive care, this study investigated the impact of medical cannabis use on oncological outcomes in patients with ovarian cancer undergoing PARPi therapy. Methods The study included patients from a single institution database treated
-
Malnutrition is associated with poor survival in women receiving radiotherapy for cervical cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Janna Laan, Luc van Lonkhuijzen, Karel Hinnen, Bradley Pieters, Inge Dekker, Lukas Stalpers, Henrike Westerveld
Objective Cancer patients are at risk of malnutrition, which is associated with poor oncological outcomes. The aim of this study was to assess the incidence of malnutrition before, during, and after radiotherapy in locally advanced cervical cancer patients. In addition, we evaluated the impact of malnutrition on survival, and whether and when malnourished patients were referred to a dietitian. Methods
-
Who takes care of the patient? Ovarian cancer management in an ESGO ovarian cancer center of excellence Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 David Johannes Krankenberg, Jalid Sehouli
The multi-modal management of ovarian cancer patients has evolved over the last decades from a linear to a holistic, patient-centered approach involving not only medical specialists but also complementary services aimed at improving both the quality of life and medical outcomes for the patient.[1][1
-
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Domenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, Claire Cropet, Cristina Caballero, Pia Wolfrum-Ristau, Toyomi Satoh, Ignace Vergote, Gabriella Parma, Trine J Nøttrup, Coriolan Lebreton, Peter A Fasching, Carmela Pisano, Luis Manso, Hugues Bourgeois, Ingo Runnebaum, Claudio Zamagni, Anne-Claire Hardy-Bessard, Andreas Schnelzer, Michel Fabbro, Barbara Schmalfeldt, Dominique Berton, Antje
Objective In the PAOLA-1/ENGOT-ov25 trial ([NCT02477644][1]), adding maintenance olaparib to bevacizumab provided a substantial progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and homologous recombination deficiency (HRD)-positive tumors, irrespective of clinical risk. Subsequently, a clinically meaningful improvement in overall survival was reported with
-
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Giorgio Bogani, Robert L Coleman, Ignace Vergote, Toon van Gorp, Isabelle Ray-Coquard, Ana Oaknin, Ursula Matulonis, David O’Malley, Francesco Raspagliesi, Giovanni Scambia, Bradley J Monk
Mirvetuximab soravtansine-gynx (MIRV) is a conjugate of a folate receptor alpha (FRα)-directed antibody and the maytansinoid microtubule inhibitor, DM4. Accumulating pre-clinical and clinical data supported the safety and anti-tumor activity of MIRV in tumors expressing FRα. In 2017, a phase I expansion study reported the first experience of MIRV in FRα-positive platinum-resistant ovarian cancer with
-
Predictors and outcomes of same day discharge after minimally invasive hysterectomy in gynecologic oncology within the National Surgical Quality Improvement Program database Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Tal Milman, Azusa Maeda, Brenna E Swift, Geneviève Bouchard-Fortier
Objective To assess trends over time of same day discharge after minimally invasive hysterectomy in oncology, identify perioperative factors influencing same day discharge, and evaluate 30 day postoperative morbidity. Methods A retrospective cohort of elective minimally invasive hysterectomies performed for gynecologic oncologic indications between January 2013 and December 2021 was identified using
-
Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023 Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Joanna Kacperczyk-Bartnik, Nicolò Bizzarri, Tibor Andrea Zwimpfer, Houssein El Hajj, Martina Aida Angeles, Richard Tóth, Charalampos Theofanakis, Esra Bilir, Khayal Gasimli, Aleksandra Natalia Strojna, Tanja Nikolova, Ali Ayhan, Domenica Lorusso, Luis Chiva
The ‘Best of ESGO 2023’ manuscript comprises a compilation of the best original research presented during the European Society of Gynaecologic Oncology annual congress held in Istanbul between September 28 and October 1, 2023. Out of 1030 submitted abstracts, 33 studies presented during the Best Oral Sessions, Mini Oral Sessions, and Young Investigator Session were selected by the ESGO Abstract Committee
-
Laparoscopic para-aortic lymphadenectomy in cases of retro-aortic left renal vein Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Giuseppe Cucinella, Vito Chiantera
Vascular anomalies involving the renal veins are rare; the overall prevalence for a retro-aortic renal vein is 3%. A patient diagnosed with serous ovarian cancer underwent a laparoscopic surgical restaging, including hysterectomy, omentectomy, peritoneal biopsies, bilateral pelvic lymphadenectomy,
-
Phase I study of ombrabulin in combination with paclitaxel and carboplatin in Japanese patients with advanced solid tumors Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Koji Matsumoto, Yoshinori Sunaga, Evelyne Ecstein-Fraisse, Keiichi Fujiwara
Objectives To evaluate the maximum tolerated dose/maximum administered dose, safety, pharmacokinetic, and efficacy profiles of ombrabulin combined with paclitaxel and carboplatin in Japanese patients with solid tumors. Methods Ombrabulin (25, 30, or 35 mg/m2) combined with paclitaxel (175 or 200 mg/m2) and carboplatin (AUC5 or AUC6) was administered by intravenous infusion once every 3 weeks to patients
-
Training the gynecologic oncologists of the future – challenges and opportunities Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Ben-Lawrence Kemah, Nanak Bhagat, Aayushi Pandya, Richard Sullivan, Sudha S Sundar
Several recent advances in gynecologic cancer care have improved patient outcomes. These include national screening and vaccination programs for cervical cancer as well as neoadjuvant chemotherapy for ovarian cancer. Conversely, these advances have cumulatively reduced surgical opportunities for training creating a need to supplement existing training strategies with evidence-based adjuncts. Technologies
-
Laparoscopic sigmoidectomy with ghost ileostomy in ovarian cancer recurrence Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Pablo Padilla-Iserte, Manel Montesinos-Albert, Marta Arnaez, Victor Lago, Matteo Frasson, Luis Matute, Santiago Domingo
In relapsed ovarian cancer, systemic treatment has been the standard of care. However, recent studies, such as the Desktop III study, have indicated that cytoreductive surgery followed by chemotherapy can lead to longer overall survival compared with chemotherapy alone.[1][1] These findings may
-
Alternatives of the pelvic sentinel lymph node migration pathway in early ovarian cancer: the simplest the best Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Victor Lago, Marta Arnaez, Pablo Padilla-Iserte, Alberto Rafael Guijarro-Campillo, Luis Matute, Marta Gurrea, Pilar Bello, Santiago Domingo
The sentinel lymph node technique in apparent early-stage ovarian cancer represents an emerging surgery, with increasing evidence published in recent years.[1][1] Lymphatic migration from the ovary is bidirectional, but after adnexectomy it becomes unidirectional towards the pelvic and aortic field
-
Clinical and pathological overview of endometrial endometrioid carcinoma Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-04-01 Mohamed Maher, Breann Angelica Zeches, Anas Mohamed
Endometrial endometrioid carcinoma is a malignant epithelial tumor with endometrioid differentiation that recapitulates the glandular-columnar nature of benign endometrium. It represents over 80% of uterine corpus carcinomas, mostly affecting elderly women (90% >50 years, median patient age 63 years
-
How to reduce anterior resection syndrome and post-operative complication after rectosigmoid resection Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-28 Giulio Ricotta, Elodie Gauroy, Anne-Sophie Navarro, Alejandra Martinez, Gwenael Ferron
Intestinal surgery is often required in the management of patients with gynecological malignancies, and the rectosigmoid colon is the bowel segment most frequently involved.[1 2][1] In rectal cancer, the total mesorectal excision technique represents the standard procedure for surgical excision.
-
Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with BRCA mutated advanced high grade serous ovarian cancer: 10 year survival analysis Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-28 Soyoun Rachel Kim, Ashna Parbhakar, Xuan Li, Marcus Q Bernardini, Liat Hogen, Taymaa May
Objectives Given the high response to platinum based chemotherapy in BRCA 1/2 mutated high grade serous ovarian cancers, there is uncertainty about the relative benefits of primary cytoreductive surgery versus neoadjuvant chemotherapy in this population. We aimed to compare the survival outcomes for women with BRCA 1/2 mutated high grade serous ovarian cancers undergoing either primary cytoreductive
-
Patient satisfaction with ultrasound, whole-body CT and whole-body diffusion-weighted MRI for pre-operative ovarian cancer staging: a multicenter prospective cross-sectional survey Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-26 Patrícia Pinto, Lil Valentin, Martina Borčinová, Markéta Wiesnerová, Fruhauf Filip, Andrea Burgetova, Martin Masek, Lukas Lambert, Valentina Chiappa, Dorella Franchi, Antonia Carla Testa, Francesca Moro, Giacomo Avesani, Camilla Panico, Sarah Alessi, Paola Pricolo, Raffaella Vigorito, Giuseppina Calareso, Roman Kocian, Jiri Slama, Anna Fagotti, Ailyn Mariela Vidal Urbinati, Mauro Signorelli, Francesca
Background In addition to the diagnostic accuracy of imaging methods, patient-reported satisfaction with imaging methods is important. Objective To report a secondary outcome of the prospective international multicenter Imaging Study in Advanced ovArian Cancer (ISAAC Study), detailing patients’ experience with abdomino-pelvic ultrasound, whole-body contrast-enhanced computed tomography (CT), and whole-body
-
Ovarian cancer during fertility follow-up Int. J. Gynecol. Cancer (IF 4.8) Pub Date : 2024-03-26 Almudena Jiménez, Luis Chiva
A patient in her 30s with a 2-year history of infertility underwent serial ultrasound monitoring to assess follicular development for pregnancy planning. During the evaluation a previously non-existent lesion was identified in the left ovary, characterized by a 2.5 cm solid multilocular lesion